Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Autores
Moreno, Carolina; Bardach, Ariel Esteban; Palermo, María Carolina; Sandoval, María Macarena; Baumeister, Elsa; Ruvinsky, Silvina Denise; Ulloa Gutiérrez, Rolando; Stegelmann, Katharina; Ardiles Ruesjas, Sofía; LaRotta, Jorge; Sini de Almeida, Rodrigo; Ciapponi, Agustín
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
This Systematic Review assesses the economic impact of Respiratory Syncytial Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource utilization and associated costs. We searched online databases from January 2012 to November 2022 to identify eligible publications. We identified 12 publications that reported direct costs, indirect costs, and resources associated with RSV and its complications. The primary direct medical resources reported were medical services, diagnostics tests and procedures, and length of stay (LOS). Direct total costs per patient ranged widely from $563 to $19,076. Direct costs are, on average, 98% higher than indirect costs. Brazil reported a higher total cost per patient than Colombia, El Salvador, México, Panamá, and Puerto Rico, while for indirect costs per patient, El Salvador and Panamá had higher costs than Brazil, Colombia, and Mexico. The mean LOS in the general ward due to RSV was 6.9 days (range 4 to 20 days) and the mean Intensive Care Unit LOS was 9.1 days (range 4 to 16 days). In many countries of the LAC region, RSV represents a considerable economic burden on health systems, but significant evidence gaps were identified in the region. More rigorous health economic studies are essential to better understand this burden and to promote effective healthcare through an informed decision-making process. Vaccination against RSV plays a critical role in mitigating this burden and should be a priority in public health strategies.
Fil: Moreno, Carolina. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Palermo, María Carolina. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Sandoval, María Macarena. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Baumeister, Elsa. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina
Fil: Ruvinsky, Silvina Denise. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
Fil: Ulloa Gutiérrez, Rolando. Hospital Nacional de Niños “Dr. Carlos Sáenz Herrera”; Argentina
Fil: Stegelmann, Katharina. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Ardiles Ruesjas, Sofía. Universidad de Barcelona; España
Fil: LaRotta, Jorge. Latin America Pfizer SAS; Colombia
Fil: Sini de Almeida, Rodrigo. Pfizer; Brasil
Fil: Ciapponi, Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Materia
RESPIRATORY SYNCYTIAL VIRUS
IMMUNOTHERAPY
COST OF ILLNESS
LATIN AMERICA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/267408
Acceder
id CONICETDig_2391fff86ad8bcf708157cb4243ff733
oai_identifier_str oai:ri.conicet.gov.ar:11336/267408
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Economic burden of respiratory syncytial virus disease in Latin America: A systematic reviewMoreno, CarolinaBardach, Ariel EstebanPalermo, María CarolinaSandoval, María MacarenaBaumeister, ElsaRuvinsky, Silvina DeniseUlloa Gutiérrez, RolandoStegelmann, KatharinaArdiles Ruesjas, SofíaLaRotta, JorgeSini de Almeida, RodrigoCiapponi, AgustínRESPIRATORY SYNCYTIAL VIRUSIMMUNOTHERAPYCOST OF ILLNESSLATIN AMERICAhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3This Systematic Review assesses the economic impact of Respiratory Syncytial Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource utilization and associated costs. We searched online databases from January 2012 to November 2022 to identify eligible publications. We identified 12 publications that reported direct costs, indirect costs, and resources associated with RSV and its complications. The primary direct medical resources reported were medical services, diagnostics tests and procedures, and length of stay (LOS). Direct total costs per patient ranged widely from $563 to $19,076. Direct costs are, on average, 98% higher than indirect costs. Brazil reported a higher total cost per patient than Colombia, El Salvador, México, Panamá, and Puerto Rico, while for indirect costs per patient, El Salvador and Panamá had higher costs than Brazil, Colombia, and Mexico. The mean LOS in the general ward due to RSV was 6.9 days (range 4 to 20 days) and the mean Intensive Care Unit LOS was 9.1 days (range 4 to 16 days). In many countries of the LAC region, RSV represents a considerable economic burden on health systems, but significant evidence gaps were identified in the region. More rigorous health economic studies are essential to better understand this burden and to promote effective healthcare through an informed decision-making process. Vaccination against RSV plays a critical role in mitigating this burden and should be a priority in public health strategies.Fil: Moreno, Carolina. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaFil: Palermo, María Carolina. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Sandoval, María Macarena. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Baumeister, Elsa. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; ArgentinaFil: Ruvinsky, Silvina Denise. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Ulloa Gutiérrez, Rolando. Hospital Nacional de Niños “Dr. Carlos Sáenz Herrera”; ArgentinaFil: Stegelmann, Katharina. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Ardiles Ruesjas, Sofía. Universidad de Barcelona; EspañaFil: LaRotta, Jorge. Latin America Pfizer SAS; ColombiaFil: Sini de Almeida, Rodrigo. Pfizer; BrasilFil: Ciapponi, Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaTaylor & Francis2024-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/267408Moreno, Carolina; Bardach, Ariel Esteban; Palermo, María Carolina; Sandoval, María Macarena; Baumeister, Elsa; et al.; Economic burden of respiratory syncytial virus disease in Latin America: A systematic review; Taylor & Francis; Human Vaccines & Immunotherapeutics; 20; 1; 7-2024; 1-92164-55152164-554XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/21645515.2024.2381298info:eu-repo/semantics/altIdentifier/doi/10.1080/21645515.2024.2381298info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:47:54Zoai:ri.conicet.gov.ar:11336/267408instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:47:54.78CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Economic burden of respiratory syncytial virus disease in Latin America: A systematic review
title Economic burden of respiratory syncytial virus disease in Latin America: A systematic review
spellingShingle Economic burden of respiratory syncytial virus disease in Latin America: A systematic review
Moreno, Carolina
RESPIRATORY SYNCYTIAL VIRUS
IMMUNOTHERAPY
COST OF ILLNESS
LATIN AMERICA
title_short Economic burden of respiratory syncytial virus disease in Latin America: A systematic review
title_full Economic burden of respiratory syncytial virus disease in Latin America: A systematic review
title_fullStr Economic burden of respiratory syncytial virus disease in Latin America: A systematic review
title_full_unstemmed Economic burden of respiratory syncytial virus disease in Latin America: A systematic review
title_sort Economic burden of respiratory syncytial virus disease in Latin America: A systematic review
dc.creator.none.fl_str_mv Moreno, Carolina
Bardach, Ariel Esteban
Palermo, María Carolina
Sandoval, María Macarena
Baumeister, Elsa
Ruvinsky, Silvina Denise
Ulloa Gutiérrez, Rolando
Stegelmann, Katharina
Ardiles Ruesjas, Sofía
LaRotta, Jorge
Sini de Almeida, Rodrigo
Ciapponi, Agustín
author Moreno, Carolina
author_facet Moreno, Carolina
Bardach, Ariel Esteban
Palermo, María Carolina
Sandoval, María Macarena
Baumeister, Elsa
Ruvinsky, Silvina Denise
Ulloa Gutiérrez, Rolando
Stegelmann, Katharina
Ardiles Ruesjas, Sofía
LaRotta, Jorge
Sini de Almeida, Rodrigo
Ciapponi, Agustín
author_role author
author2 Bardach, Ariel Esteban
Palermo, María Carolina
Sandoval, María Macarena
Baumeister, Elsa
Ruvinsky, Silvina Denise
Ulloa Gutiérrez, Rolando
Stegelmann, Katharina
Ardiles Ruesjas, Sofía
LaRotta, Jorge
Sini de Almeida, Rodrigo
Ciapponi, Agustín
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv RESPIRATORY SYNCYTIAL VIRUS
IMMUNOTHERAPY
COST OF ILLNESS
LATIN AMERICA
topic RESPIRATORY SYNCYTIAL VIRUS
IMMUNOTHERAPY
COST OF ILLNESS
LATIN AMERICA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv This Systematic Review assesses the economic impact of Respiratory Syncytial Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource utilization and associated costs. We searched online databases from January 2012 to November 2022 to identify eligible publications. We identified 12 publications that reported direct costs, indirect costs, and resources associated with RSV and its complications. The primary direct medical resources reported were medical services, diagnostics tests and procedures, and length of stay (LOS). Direct total costs per patient ranged widely from $563 to $19,076. Direct costs are, on average, 98% higher than indirect costs. Brazil reported a higher total cost per patient than Colombia, El Salvador, México, Panamá, and Puerto Rico, while for indirect costs per patient, El Salvador and Panamá had higher costs than Brazil, Colombia, and Mexico. The mean LOS in the general ward due to RSV was 6.9 days (range 4 to 20 days) and the mean Intensive Care Unit LOS was 9.1 days (range 4 to 16 days). In many countries of the LAC region, RSV represents a considerable economic burden on health systems, but significant evidence gaps were identified in the region. More rigorous health economic studies are essential to better understand this burden and to promote effective healthcare through an informed decision-making process. Vaccination against RSV plays a critical role in mitigating this burden and should be a priority in public health strategies.
Fil: Moreno, Carolina. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Palermo, María Carolina. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Sandoval, María Macarena. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Baumeister, Elsa. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina
Fil: Ruvinsky, Silvina Denise. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina
Fil: Ulloa Gutiérrez, Rolando. Hospital Nacional de Niños “Dr. Carlos Sáenz Herrera”; Argentina
Fil: Stegelmann, Katharina. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Ardiles Ruesjas, Sofía. Universidad de Barcelona; España
Fil: LaRotta, Jorge. Latin America Pfizer SAS; Colombia
Fil: Sini de Almeida, Rodrigo. Pfizer; Brasil
Fil: Ciapponi, Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
description This Systematic Review assesses the economic impact of Respiratory Syncytial Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource utilization and associated costs. We searched online databases from January 2012 to November 2022 to identify eligible publications. We identified 12 publications that reported direct costs, indirect costs, and resources associated with RSV and its complications. The primary direct medical resources reported were medical services, diagnostics tests and procedures, and length of stay (LOS). Direct total costs per patient ranged widely from $563 to $19,076. Direct costs are, on average, 98% higher than indirect costs. Brazil reported a higher total cost per patient than Colombia, El Salvador, México, Panamá, and Puerto Rico, while for indirect costs per patient, El Salvador and Panamá had higher costs than Brazil, Colombia, and Mexico. The mean LOS in the general ward due to RSV was 6.9 days (range 4 to 20 days) and the mean Intensive Care Unit LOS was 9.1 days (range 4 to 16 days). In many countries of the LAC region, RSV represents a considerable economic burden on health systems, but significant evidence gaps were identified in the region. More rigorous health economic studies are essential to better understand this burden and to promote effective healthcare through an informed decision-making process. Vaccination against RSV plays a critical role in mitigating this burden and should be a priority in public health strategies.
publishDate 2024
dc.date.none.fl_str_mv 2024-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/267408
Moreno, Carolina; Bardach, Ariel Esteban; Palermo, María Carolina; Sandoval, María Macarena; Baumeister, Elsa; et al.; Economic burden of respiratory syncytial virus disease in Latin America: A systematic review; Taylor & Francis; Human Vaccines & Immunotherapeutics; 20; 1; 7-2024; 1-9
2164-5515
2164-554X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/267408
identifier_str_mv Moreno, Carolina; Bardach, Ariel Esteban; Palermo, María Carolina; Sandoval, María Macarena; Baumeister, Elsa; et al.; Economic burden of respiratory syncytial virus disease in Latin America: A systematic review; Taylor & Francis; Human Vaccines & Immunotherapeutics; 20; 1; 7-2024; 1-9
2164-5515
2164-554X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/21645515.2024.2381298
info:eu-repo/semantics/altIdentifier/doi/10.1080/21645515.2024.2381298
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268889504808960
score 13.13397

Publicaciones similares